Implementation of Rapid CYP2C19 Genotyping to Guide Antiplatelet Therapy for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack.
Clopidogrel is first-line for secondary stroke prevention, but its effectiveness is affected by CYP2C19 genetic variation. An American Heart Association (AHA) scientific statement concluded that CYP2C19-guided P2Y12 inhibitor (P2Y12i) therapy is evidence-supported, though real-world application depends on implementatio...